Consensus Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-01-16 EST			5-day change	1st Jan Change
4.240 ^USD	0.00%		+5.47%	+17.45%

01-05	Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH	CI
01-05	Altimmune Says US FDA Grants Breakthrough Therapy Designation for Pemvidutide in MASH	MT

Evolution of the Average Target: Altimmune, Inc.

Evolution of the Target Price: Altimmune, Inc.

Changes in Analyst Recommendations: Altimmune, Inc.

a2c17d8c686c01f953f606c1629.WsNebkWyhHx51vxpTka2v_HOXlcP9t4ukyaeLB6wmZM.KqIECCv0szQcr5kDfBSb1Yv2MWR7v69F3GGzWlWB3L4IijUYLMHFFAmaxA~9049f6dd3356158f4a6dfb543ac1ceda

Analysts' recommendations: Altimmune, Inc.

25-08-13	UBS Adjusts Price Target on Altimmune to $24 From $26, Maintains Buy Rating	MT
25-08-13	B. Riley Adjusts Price Target on Altimmune to $18 From $20, Maintains Buy Rating	MT
25-02-28	William Blair Initiates Altimmune at Market Perform	MT
25-01-08	Stifel Initiates Altimmune at Buy With $18 Price Target	MT
24-11-12	UBS Initiates Altimmune at Buy With $26 Price Target	MT
24-04-29	Altimmune Shares Decline After Guggenheim Downgrade	MT
24-04-29	Guggenheim Downgrades Altimmune to Neutral From Buy	MT
24-01-17	B. Riley Raises Altimmune's PT to $20 From $15 on Increased Obesity+NASH Therapeutics' Product Sales Projections; Keeps Buy Rating	MT
23-11-09	B. Riley Lowers Altimmune's PT to 8 From $15, Says Updated Model Adjusts for Ongoing Obesity+NASH Market Dynamics; Maintains Buy Rating	MT
23-08-14	HC Wainwright Adjusts Price Target on Altimmune to $15 From $50, Maintains Buy Rating	MT
23-08-11	B. Riley Lowers Altimmune's Price Target to $15 From $20, Keeps Buy Rating	MT
23-08-10	B. Riley Lowers Altimmune's Price Target to $20 From $26, Keeps Buy Rating	MT
23-03-22	Goldman Sachs Downgrades Altimmune to Neutral From Buy, Adjusts Price Target to $6 From $20	MT
23-01-20	HC Wainwright Reiterates Altimmune at Buy With $50 Price Target	MT
23-01-18	Evercore ISI Adjusts Altimmune Price Target to $25 From $14, Maintains Outperform Rating	MT
22-12-01	Goldman Sachs Initiates Altimmune at Buy With $20 Price Target	MT
22-11-11	JMP Securities Adjusts Price Target on Altimmune to $26 From $28, Maintains Market Outperform Rating	MT
22-09-28	Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight	CI
22-09-16	Guggenheim Adjusts Altimmune's Price Target to $26 From $31, Reiterates Buy Rating	MT
22-08-31	Jefferies Adjusts Altimmune's Price Target to $35 From $30, Reiterates Buy Rating	MT
22-08-17	HC Wainwright Adjusts Altimmune's Price Target to $50 From $25, Reiterates Buy Rating	MT
22-08-12	B. Riley Securities Raises Altimmune's Price Target to $26 from $21, Increases Likelihood of Technical, Regulatory Success; Keeps Buy Rating	MT
22-05-18	Piper Sandler Adjusts Altimmune's Price Target to $25 From $34, Reiterates Overweight Rating	MT
22-03-16	Guggenheim Adjusts Altimmune's Price Target to $28 From $33, Reiterates Buy Rating	MT
22-01-24	B. Riley Lowers Altimmune's Price Target to $21 from $27 After Revising Cost Capital Assumptions, Keeps Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALTIMMUNE, INC.					+318.63%
	ARGENX SE					+18.83%
	WUXI APPTEC CO., LTD.					+24.54%
	INSMED INCORPORATED					+32.54%
	BIONTECH SE					+26.81%
	WUXI BIOLOGICS (CAYMAN) INC.					+2.93%
	GENMAB A/S					-1.58%
	AKESO, INC.					+42.51%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+12.44%
	SUMMIT THERAPEUTICS INC.					+90.21%
	Average					+56.79%
	Weighted average by Cap.					+25.12%